TY - JOUR
T1 - Development and Validation of a Comprehensive Model to Estimate Early Allograft Failure Among Patients Requiring Early Liver Retransplant
AU - Avolio, Alfonso Wolfango
AU - Franco, Antonio
AU - Schlegel, Andrea
AU - Lai, Quirino
AU - Meli, Sonia
AU - Burra, Patrizia
AU - Patrono, Damiano
AU - Ravaioli, Matteo
AU - Bassi, Domenico
AU - Ferla, Fabio
AU - Pagano, Duilio
AU - Violi, Paola
AU - Camagni, Stefania
AU - Dondossola, Daniele
AU - Montalti, Roberto
AU - Alrawashdeh, Wasfi
AU - Vitale, Alessandro
AU - Teofili, Luciana
AU - Spoletini, Gabriele
AU - Magistri, Paolo
AU - Bongini, Marco
AU - Rossi, Massimo
AU - Mazzaferro, Vincenzo
AU - Di Benedetto, Fabrizio
AU - Hammond, John
AU - Vivarelli, Marco
AU - Agnes, Salvatore
AU - Colledan, Michele
AU - Carraro, Amedeo
AU - Cescon, Matteo
AU - De Carlis, Luciano
AU - Caccamo, Lucio
AU - Gruttadauria, Salvatore
AU - Muiesan, Paolo
AU - Cillo, Umberto
AU - Romagnoli, Renato
AU - De Simone, Paolo
PY - 2020
Y1 - 2020
N2 - ABSTRACT
BACKGROUND
Expansion of donor acceptance criteria for liver transplantation increased the risk for early allograft failure (EAF). Though EAF prediction is pivotal to optimize transplant outcomes, there is no consensus on specific EAF indicators or timing to evaluate EAF. Recently, the Liver Graft Assessment following Transplantation (L-GrAFT) algorithm, based on aspartate transaminase, bilirubin, platelets, and INR kinetics, has been developed from a single-center database gathered from 2002 to 2015.
OBJECTIVE
To develop and validate a simplified comprehensive model estimating the EAF risk at day 10 after liver transplantation (the Early Allograft failure Simplified Estimation, EASE score), and, secondarily, to early identify patients with unsustainable EAF risk, suitable for re-transplant.
DESIGN
This multicenter study was designed to elaborate a score catching the continuum from normal graft function to non-function after transplant. We included among EAF determinants both parenchymal and vascular factors, which provide an indication to list for re-transplant. The L-GrAFT kinetic approach was adopted and modified with less data-entries and novel variables. ClinicalTrials.gov Identifier: NCT03858088.
SETTING
The patient population included 1,609 Italian patients in the derivation set and 570 UK patients in the validation set, all transplanted in 2016 and 2017.
MAIN OUTCOME and MEASURE
EAF was defined as graft failure (codified by re-transplant or death) for any reason within day 90 after transplant.
RESULTS
The EAF incidence was 6.8%. The EASE score was developed through 17 entries derived from 8 variables: MELD, blood transfusions, early thrombosis of hepatic vessels, kinetic parameters of transaminases, platelets and bilirubin. Donor parameters (age, DCD, machine perfusion) were not predictive. Results were adjusted for Center-volume.
At ROC curve analysis, the EASE score outperformed L-GrAFT, MEAF, EAD, ET-DRI, DMELD, and DRI scores, predicting day-90 EAF in 87% of cases. Patients could be stratified in five classes, with those in the highest class exhibiting an unsustainable EAF risk.
CONCLUSIONS AND RELEVANCE
The EASE score reliably predicts the EAF risk. Knowledge of contributing factors may help clinicians to mitigate risk factors and guide through the challenging clinical decision to allocate patients to early liver re-transplantation. EASE may be used in translational research across transplant Centers.
AB - ABSTRACT
BACKGROUND
Expansion of donor acceptance criteria for liver transplantation increased the risk for early allograft failure (EAF). Though EAF prediction is pivotal to optimize transplant outcomes, there is no consensus on specific EAF indicators or timing to evaluate EAF. Recently, the Liver Graft Assessment following Transplantation (L-GrAFT) algorithm, based on aspartate transaminase, bilirubin, platelets, and INR kinetics, has been developed from a single-center database gathered from 2002 to 2015.
OBJECTIVE
To develop and validate a simplified comprehensive model estimating the EAF risk at day 10 after liver transplantation (the Early Allograft failure Simplified Estimation, EASE score), and, secondarily, to early identify patients with unsustainable EAF risk, suitable for re-transplant.
DESIGN
This multicenter study was designed to elaborate a score catching the continuum from normal graft function to non-function after transplant. We included among EAF determinants both parenchymal and vascular factors, which provide an indication to list for re-transplant. The L-GrAFT kinetic approach was adopted and modified with less data-entries and novel variables. ClinicalTrials.gov Identifier: NCT03858088.
SETTING
The patient population included 1,609 Italian patients in the derivation set and 570 UK patients in the validation set, all transplanted in 2016 and 2017.
MAIN OUTCOME and MEASURE
EAF was defined as graft failure (codified by re-transplant or death) for any reason within day 90 after transplant.
RESULTS
The EAF incidence was 6.8%. The EASE score was developed through 17 entries derived from 8 variables: MELD, blood transfusions, early thrombosis of hepatic vessels, kinetic parameters of transaminases, platelets and bilirubin. Donor parameters (age, DCD, machine perfusion) were not predictive. Results were adjusted for Center-volume.
At ROC curve analysis, the EASE score outperformed L-GrAFT, MEAF, EAD, ET-DRI, DMELD, and DRI scores, predicting day-90 EAF in 87% of cases. Patients could be stratified in five classes, with those in the highest class exhibiting an unsustainable EAF risk.
CONCLUSIONS AND RELEVANCE
The EASE score reliably predicts the EAF risk. Knowledge of contributing factors may help clinicians to mitigate risk factors and guide through the challenging clinical decision to allocate patients to early liver re-transplantation. EASE may be used in translational research across transplant Centers.
KW - LIVER TRANSPLANTATION, EARLY ALLOGRAFT FAILURE, OUTCOME, RISK QUANTIFICATION
KW - TRAPIANTO DI FEGATO, SOPRAVVIVENZA, QUANTIFICAZIONE DEL RISCHIO
KW - li
KW - LIVER TRANSPLANTATION, EARLY ALLOGRAFT FAILURE, OUTCOME, RISK QUANTIFICATION
KW - TRAPIANTO DI FEGATO, SOPRAVVIVENZA, QUANTIFICAZIONE DEL RISCHIO
KW - li
UR - http://hdl.handle.net/10807/159050
UR - https://jamanetwork.com/journals/jamasurgery
U2 - 10.1001/jamasurg.2020.4095
DO - 10.1001/jamasurg.2020.4095
M3 - Article
SN - 2168-6254
VL - 155
SP - 1
EP - 12
JO - JAMA Surgery
JF - JAMA Surgery
ER -